NJ Adopts ERT Solution for Suicide Monitoring in Students
ERT, a leading provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, today announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University
ERT, a provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University Behavioral Health Care (UBHC) as part of the New Jersey Youth Suicide Prevention Project (NJYSPP). Beginning this semester, AVERT will be used to identify and routinely assess suicide risk among high school and college students in six targeted NJ counties (Bergen, Camden, Hudson, Passaic, Middlesex and Monmouth). Suicide is the second leading cause of death among 15 to 24 year olds in the United States (2012). Funded by a grant administered by the Substance Abuse and Mental Health Services Administration, the NJYSPP is a comprehensive approach to youth suicide prevention, which provides gatekeepers in the counties with best-practice and evidence-based trainings in suicide prevention, intervention, and postvention at no charge. By using the AVERT self-assessment system, the NJYSPP’s objective is to help school-based gatekeepers proactively identify at-risk students and more efficiently refer them to trained mental health professionals in their community. Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
